{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:24:22Z","timestamp":1791282262274,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epoxy-fatty-acids (EpFAs), cytochrome P450 dependent arachidonic acid derivatives, have been suggested to have anti-inflammatory properties, though their effects on autoimmune diseases like systemic lupus erythematosus (SLE) have yet to be investigated. We assessed the influence of EpFAs and their metabolites in lupus prone NZB\/W F1 mice by pharmacological inhibition of soluble epoxide hydrolase (sEH, EPHX2). The sEH inhibitor 1770 was administered to lupus prone NZB\/W F1 mice in a prophylactic and a therapeutic setting. Prophylactic inhibition of sEH significantly improved survival and reduced proteinuria. By contrast, sEH inhibitor-treated nephritic mice had no survival benefit; however, histological changes were reduced when compared to controls. In humans, urinary EpFA levels were significantly different in 47 SLE patients when compared to 10 healthy controls. Gene expression of EPHX2 was significantly reduced in the kidneys of both NZB\/W F1 mice and lupus nephritis (LN) patients. Correlation of EpFAs with SLE disease activity and reduced renal EPHX gene expression in LN suggest roles for these components in human disease.<\/jats:p>","DOI":"10.1038\/s41598-019-45299-5","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:03:04Z","timestamp":1561024984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB\/W F1 mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Jan","family":"Klocke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Ulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duska","family":"Dragun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Gollasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Hagen","family":"Schunck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-8317","authenticated-orcid":false,"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Enghard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"45299_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","volume":"53","author":"C Morisseau","year":"2013","unstructured":"Morisseau, C. & Hammock, B. D. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. 53, 37\u201358 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"45299_CR2","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1074\/jbc.RA117.000298","volume":"293","author":"ML Edin","year":"2018","unstructured":"Edin, M. L. et al. Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia. J. Biol. Chem. 293, 3281\u20133292 (2018).","journal-title":"J. Biol. Chem."},{"key":"45299_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","volume":"526","author":"TR Harris","year":"2013","unstructured":"Harris, T. R. & Hammock, B. D. Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526, 61\u201374 (2013).","journal-title":"Gene"},{"key":"45299_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","volume":"180","author":"KM Wagner","year":"2017","unstructured":"Wagner, K. M., McReynolds, C. B., Schmidt, W. K. & Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol. Ther. 180, 62\u201376 (2017).","journal-title":"Pharmacol. Ther."},{"key":"45299_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276\u20131279 (1999).","journal-title":"Science"},{"key":"45299_CR6","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1073\/pnas.0503279102","volume":"102","author":"KR Schmelzer","year":"2005","unstructured":"Schmelzer, K. R. et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl Acad. Sci. USA 102, 9772\u20139777 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45299_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","volume":"46","author":"JD Imig","year":"2005","unstructured":"Imig, J. D. et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46, 975\u2013981 (2005).","journal-title":"Hypertension"},{"key":"45299_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1042\/CS20080039","volume":"116","author":"JJ Olearczyk","year":"2009","unstructured":"Olearczyk, J. J. et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond.) 116, 61\u201370 (2009).","journal-title":"Clin. Sci. (Lond.)"},{"key":"45299_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.prostaglandins.2013.01.002","volume":"104\u2013105","author":"JD Imig","year":"2013","unstructured":"Imig, J. D. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat. 104\u2013105, 2\u20137 (2013).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"45299_CR10","doi-asserted-by":"publisher","first-page":"e12259","DOI":"10.1111\/1755-5922.12259","volume":"35","author":"O Islam","year":"2017","unstructured":"Islam, O. et al. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive and diabetic rats. Cardiovasc. Ther. 35, e12259 (2017).","journal-title":"Cardiovasc. Ther."},{"key":"45299_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jnc.13933","volume":"140","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation. J. Neurochem. 140, 814\u2013825 (2017).","journal-title":"J. Neurochem."},{"key":"45299_CR12","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1038\/sj.jcbfm.9600494","volume":"27","author":"W Zhang","year":"2007","unstructured":"Zhang, W. et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27, 1931\u20131940 (2007).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"45299_CR13","doi-asserted-by":"publisher","first-page":"L1213","DOI":"10.1152\/ajplung.00394.2016","volume":"311","author":"M Wepler","year":"2016","unstructured":"Wepler, M. et al. Soluble epoxide hydrolase deficiency or inhibition enhances murine hypoxic pulmonary vasoconstriction after lipopolysaccharide challenge. Am. J. Physiol. Lung Cell. Mol. Physiol. 311, L1213\u2013L1221 (2016).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"45299_CR14","doi-asserted-by":"publisher","first-page":"F496","DOI":"10.1152\/ajprenal.00350.2004","volume":"289","author":"JD Imig","year":"2005","unstructured":"Imig, J. D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289, F496\u2013503 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"45299_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.prostaglandins.2009.04.004","volume":"89","author":"M Sharma","year":"2009","unstructured":"Sharma, M. et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat. 89, 43\u201351 (2009).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"45299_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1194\/jlr.M031914","volume":"54","author":"S Kundu","year":"2013","unstructured":"Kundu, S. et al. Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J. Lipid Res. 54, 436\u2013447 (2013).","journal-title":"J. Lipid Res."},{"key":"45299_CR17","doi-asserted-by":"publisher","first-page":"e0145645","DOI":"10.1371\/journal.pone.0145645","volume":"11","author":"Y Zhu","year":"2016","unstructured":"Zhu, Y. et al. Renal ischemia\/reperfusion injury in soluble epoxide hydrolase-deficient mice. PLoS One 11, e0145645 (2016).","journal-title":"PLoS One"},{"key":"45299_CR18","doi-asserted-by":"publisher","first-page":"e11979","DOI":"10.1371\/journal.pone.0011979","volume":"5","author":"O Jung","year":"2010","unstructured":"Jung, O. et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PloS One 5, e11979 (2010).","journal-title":"PloS One"},{"key":"45299_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ki.2010.377","volume":"79","author":"U Hoff","year":"2011","unstructured":"Hoff, U. et al. Inhibition of 20-HETE synthesis and action protects the kidney from ischemia\/reperfusion injury. Kidney Int. 79, 57\u201365 (2011).","journal-title":"Kidney Int."},{"key":"45299_CR20","doi-asserted-by":"publisher","first-page":"14189","DOI":"10.1074\/jbc.M113.458414","volume":"288","author":"A Bettaieb","year":"2013","unstructured":"Bettaieb, A. et al. Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. J. Biol. Chem. 288, 14189\u201314199 (2013).","journal-title":"J. Biol. Chem."},{"key":"45299_CR21","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.1073\/pnas.1510137112","volume":"112","author":"B Inceoglu","year":"2015","unstructured":"Inceoglu, B. et al. Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proc. Natl Acad. Sci. USA 112, 9082\u20139087 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45299_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.taap.2015.03.022","volume":"286","author":"TR Harris","year":"2015","unstructured":"Harris, T. R. et al. Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. Toxicol. Appl. Pharmacol. 286, 102\u2013111 (2015).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"45299_CR23","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/febs.14100","volume":"284","author":"A Bettaieb","year":"2017","unstructured":"Bettaieb, A. et al. Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury. FEBS J. 284, 1970\u20131986 (2017).","journal-title":"FEBS J."},{"key":"45299_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ki.1984.75","volume":"25","author":"HA Austin","year":"1984","unstructured":"Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T. & Balow, J. E. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int. 25, 689\u2013695 (1984).","journal-title":"Kidney Int."},{"key":"45299_CR25","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4049\/jimmunol.1103031","volume":"189","author":"CC Berthier","year":"2012","unstructured":"Berthier, C. C. et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J. Immunol. 189, 988\u20131001 (2012).","journal-title":"J. Immunol."},{"key":"45299_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.prostaglandins.2015.04.011","volume":"120","author":"C Roche","year":"2015","unstructured":"Roche, C. et al. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. Prostaglandins Other Lipid Mediat. 120, 148\u2013154 (2015).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"45299_CR27","doi-asserted-by":"publisher","first-page":"F971","DOI":"10.1152\/ajprenal.00256.2014","volume":"307","author":"J Kim","year":"2014","unstructured":"Kim, J., Imig, J. D., Yang, J., Hammock, B. D. & Padanilam, B. J. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am. J. Physiol. Renal Physiol. 307, F971\u2013F980 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"45299_CR28","doi-asserted-by":"publisher","first-page":"F131","DOI":"10.1152\/ajprenal.00531.2014","volume":"308","author":"J Kim","year":"2015","unstructured":"Kim, J. et al. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 308, F131\u2013F139 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"45299_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.113.01949","volume":"62","author":"A Hye Khan","year":"2013","unstructured":"Hye Khan, A. et al. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension 62, 905\u2013913 (2013).","journal-title":"Hypertension"},{"key":"45299_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1042\/CS20150778","volume":"130","author":"A Hye Khan","year":"2016","unstructured":"Hye Khan, A. et al. Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clin. Sci. (Lond.) 130, 587\u2013599 (2016).","journal-title":"Clin. Sci. (Lond.)"},{"key":"45299_CR31","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1096\/fj.12-218040","volume":"27","author":"A Hye Khan","year":"2013","unstructured":"Hye Khan, A. et al. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 27, 2946\u20132956 (2013).","journal-title":"FASEB J."},{"key":"45299_CR32","first-page":"216","volume":"5","author":"A Hye Khan","year":"2014","unstructured":"Hye Khan, A., Falck, J. R., Manthati, V. L., Campbell, W. B. & Imig, J. D. Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Front. Pharmacol. 5, 216 (2014).","journal-title":"Front. Pharmacol."},{"key":"45299_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1042\/BJ20061328","volume":"403","author":"DN Muller","year":"2007","unstructured":"Muller, D. N. et al. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem. J. 403, 109\u2013118 (2007).","journal-title":"Biochem. J."},{"key":"45299_CR34","doi-asserted-by":"publisher","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","volume":"285","author":"C Arnold","year":"2010","unstructured":"Arnold, C. et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of \u03c9-3 fatty acids. J. Biol. Chem. 285, 32720\u201332733 (2010).","journal-title":"J. Biol. Chem."},{"key":"45299_CR35","doi-asserted-by":"publisher","first-page":"7067","DOI":"10.1021\/jm100691c","volume":"53","author":"TE Rose","year":"2010","unstructured":"Rose, T. E. et al. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J. Med. Chem. 53, 7067\u20137075 (2010).","journal-title":"J. Med. Chem."},{"key":"45299_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/FJC.0000000000000094","volume":"64","author":"A Ulu","year":"2014","unstructured":"Ulu, A. et al. An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. J. Cardiovasc. Pharmacol. 64, 87\u201399 (2014).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"45299_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45299-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:42:50Z","timestamp":1671273770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45299-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45299"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45299-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"16 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BDH is a founder of EicOsis Human Health, which is supported by the NIH Blueprint Development Program to introduce sEHI into clinics for neuropathic pain. The\u00a0other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8993"}}